Domain Therapeutics develops small molecules targeting G-coupled protein receptors.
Domain Therapeutics has raised €46M across 2 funding rounds from 10 investors, most recently a Series A round in May 2022. Based in Strasbourg,, France; founded 2001; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2022-05-10 | Series A | €40M | 3B Future Health Fund,adMare BioInnovations,CTI Life Sciences,Omnes Capital,Panacea Venture,Schroders Capital+4 more | View deal → |
| 2020-01-13 | Other | €6.0M | — | View deal → |
